Treatment effects on blood oxygen percent saturation and hemolysis parameters. Change from baseline in mean absolute values for blood oxygen percent saturation (A) and hemoglobin concentration (B) and reticulocyte percentage (C) obtained from MMRM analysis shown as geometric mean ratio to baseline (90% CI) over the first 24 weeks of treatment in patients on canakinumab (red line) and placebo (blue line). Baseline mean/median (range) values for canakinumab and placebo, respectively, in blood oxygen percent saturation are as follows: 96.8/96 (range, 93-100) and 97.7/98 (range, 92-100). Patient data truncated after having received a blood transfusion.